{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:46:24Z","timestamp":1792406784270,"version":"4.4.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Ruxolitinib is first\u2010line therapy for intermediate\/high\u2010risk myelofibrosis (MF), but \u223c50% of patients discontinue within 1\u00a0year due to loss of efficacy or intolerance. Four JAK inhibitors (gecacitinib, fedratinib, pacritinib, momelotinib) are approved for ruxolitinib\u2010pretreated MF, with no head\u2010to\u2010head trials comparing their efficacy and safety. This study used matching\u2010adjusted indirect comparison (MAIC) to compare these four agents, aiming to provide evidence\u2010based insights for treatment decision\u2010making in ruxolitinib\u2010resistant or intolerant MF. Individual patient data (IPD) of gecacitinib (100\u00a0mg BID; ZGJAK006\/ZGJAK017,\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a078) and published data of comparators (fedratinib: JAKARTA\u20102\/FREEDOM2; pacritinib: PAC203; momelotinib: SIMPLIFY\u20102\/MOMENTUM) were analyzed. Eight baseline characteristics were matched. Efficacy outcomes (week\u201024 SVR35, TSS50, transfusion independence [TI]) were reported as odds ratios (ORs); safety as risk differences (RDs). Gecacitinib showed superior SVR35 versus fedratinib (JAKARTA\u20102: OR\u00a0=\u00a03.96, 95% CI\u00a0=\u00a01.37\u201311.39,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.0108), pacritinib (PAC203: OR\u00a0=\u00a06.10, 95% CI\u00a0=\u00a01.54\u201324.23,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.0101), and momelotinib (SIMPLIFY\u20102: OR\u00a0=\u00a08.65, 95% CI\u00a0=\u00a01.86\u201340.31,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.0060), and superior TSS50 versus pacritinib (OR\u00a0=\u00a07.62 95% CI\u00a0=\u00a01.84\u201331.51,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.0050) and momelotinib (MOMENTUM: OR\u00a0=\u00a07.52, 95% CI\u00a0=\u00a01.63\u201334.61,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.0096). Numerically, gecacitinib had better TI. It also had significantly lower incidences of diarrhea, nausea, and AE\u2010related treatment discontinuation. Hematologic AE profiles of gecacitinib varied by comparator cohort. Gecacitinib showed favorable efficacy and tolerability signals versus several comparators, suggesting it may be a valuable second\u2010line option.\n                  <\/jats:p>","DOI":"10.1002\/hon.70230","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:39:15Z","timestamp":1785321555000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Matching\u2010Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second\u2010Line Myelofibrosis Therapy"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-2288","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang Provincial Clinical Research Center for Hematological Disorders Zhejiang University Cancer Center  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology The Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qike","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology Gansu Provincial Hospital  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Hospital of Hebei Medical University  Shijiazhuang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Hospital of Jilin University  Changchun China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-4489","authenticated-orcid":false,"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-6300","authenticated-orcid":false,"given":"Minghui","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking Union Medical College Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangming","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology Shanxi Bethune Hospital The Third Hospital of Shanxi Medical University  Taiyuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology The Affiliated Hospital of Qingdao University  Qingdao China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibing","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanyang Medical College  Nanyang Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-5897","authenticated-orcid":false,"given":"Guangsheng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Provincial People's Hospital Key Laboratory of Hematology of Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking University Third Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology Ruijin Hospital Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital College of Clinical Medicine of Henan University of Science and Technology  Luoyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanling","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunkang","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hematology Shanghai Jiao Tong University Affiliated Sixth People's Hospital  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology Henan Provincial People's Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology Guangdong Provincial People's Hospital  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology The Third Xiangya Hospital Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology Affiliated Hospital of Guizhou Medical University  Guiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology Nanfang Hospital Southern Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Suo","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang Provincial Clinical Research Center for Hematological Disorders Zhejiang University Cancer Center  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-9915","authenticated-orcid":false,"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang Provincial Clinical Research Center for Hematological Disorders Zhejiang University Cancer Center  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100691"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1110556"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1110557"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010020\u201004002\u20109"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010017\u20103194\u20104"},{"key":"e_1_2_11_7_1","unstructured":"National Comprehensive Cancer Network. \u201cMyeloproliferative Neoplasms (Version 2.2025) \u201d2025 [cited July 8 2025] https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26857"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(17)30088\u20101"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(24)00212\u20106"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003314"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(17)30237\u20105"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(22)02036\u20100"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27033"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27031"},{"key":"e_1_2_11_17_1","unstructured":"N. M. P.Administration \u201cNMPA Approves Gecacitinib Hydrochloride Tablets in China \u201d2025 : [cited May 29 2025] https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20250529152155157.html."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26712"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27036"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009311"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(17)30027\u20103"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287576"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70152"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2511562"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2511564"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.2168.2168"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010628"},{"key":"e_1_2_11_29_1","unstructured":"A.Rohatgi2024 [cited 7 July 2025] https:\/\/automeris.io\/WebPlotDigitizer\/."},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010154"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282612"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13262"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.70230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:13:49Z","timestamp":1792404829000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/hon.70230"],"URL":"https:\/\/doi.org\/10.1002\/hon.70230","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"2026-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70230"}}